Total Body PET/CT Imaging for Myofascial Pain
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. Please consult with the study team for guidance.
What data supports the effectiveness of the drug 11C-butanol and 18F-FDG for treating myofascial pain?
The research shows that 18F-FDG PET/CT imaging can detect metabolic activity related to pain in the spinal cord, which may help in understanding pain conditions like myofascial pain. Additionally, 18F-FDG has been used to identify inflammation in low back pain, suggesting its potential usefulness in assessing pain-related conditions.12345
Is 11C-butanol safe for use in humans?
How does the treatment in the Total Body PET/CT Imaging for Myofascial Pain trial differ from other treatments for this condition?
This treatment is unique because it uses total body PET/CT imaging to detect metabolic activity related to pain, which can help identify specific areas of pain in the body. Unlike traditional treatments that focus on symptom relief, this approach aims to understand the underlying metabolic changes associated with myofascial pain.12111213
What is the purpose of this trial?
The main objective of this study is to establish novel measures derived from Total-body-Positron Emission Tomography/Computed Tomography (TB-PET/CT) as quantitative biomarkers for the investigation of myofascial pain. The TB-PET/CT assessed measures are those reflective of myofascial tissue metabolism, perfusion, and fatty infiltration.
Research Team
Lorenzo Nardo, MD
Principal Investigator
University of California, Davis
Eligibility Criteria
Adults over 18 with chronic low back pain for the past 3 months, experiencing pain more than half of the days in the last six months. Participants must have a palpable muscle nodule or taut band and be able to lay still for scans after fasting. Exclusions include pregnant individuals, those over 240 kg, people with certain medical conditions like cancer or spine issues, and anyone who can't consent in English.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Imaging
Participants undergo dynamic 18F-FDG PET/CT and 11C-butanol PET/CT scans on the EXPLORER total-body PET/CT system
Follow-up
Participants are monitored for safety and effectiveness after imaging
Treatment Details
Interventions
- 11C-butanol
- 18F-FDG
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, Davis
Lead Sponsor
National Institutes of Health (NIH)
Collaborator
National Center for Complementary and Integrative Health (NCCIH)
Collaborator